In ALS patients, elevated inflammatory markers and IL-18 levels in serum and cerebrospinal fluid, along with increased NLRP3 inflammasome and IL-18 expression in monocytes, underscore the involvement of the NLRP3 pathway [110, 111]. This evidence concerns the gene IL18 and amyotrophic lateral sclerosis.